"OncoGenex Pharmaceuticals (OGXI) recently released their fourth quarter and year end 2010 financial results; during the conference call they discussed updates in their development programs and provided an outlook for 2011," notes biotech specialist John McCamant.

The editor of the Medical Technology Stock Letter continues, "The company reported a Q4 2010 net loss of $2.8 million or ($0.26) per share compared to Q4 2009 net profit of $3.9 million or $0.70 per share.

"OGXI finished the year in a solid position financially with $85.6 million in cash. The company expects to end 2011 with $50-$54 million on the balance sheet and use $31-$35 million in operating cash. They appear to have enough cash to fund operations into 2014.

"Sangamo Biosciences (SGMO) has been receiving the kind of news that biotech companies dream of, with multiple main-stream news outlets picking up the story that the company is developing what may be a 'functional cure' for AIDS," notes biotech sector specialist John McCamant.

The editor of The Medical Technology Stock Letter explains, "The treatments that SGMO is developing are exciting, and we see this stock going much higher this year and in subsequent years based on clinical progress.

"As tradition holds, Celgene (CELG) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene's ongoing plans to become a world-wide company and expansion into global markets," reports John McCamant.

The biotech specialist and editor of The Medical Technology Stock Letter explains, "They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs.

"Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition.

"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"For a number of reasons, my top stock pick for 2011 is Affymetrix (AFFX)," says biotech sector specialist Nate Pile.

The editor of Nate's Notes explains, "This small company based in Santa Clara, CA, develops, manufactures, sells, and services equipment and consumables used in the life sciences industry to do what is know as 'high throughput genetic screening.'

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

"Gilead Sciences (GILD) is a top-rated stock on both our fundamental and technical screens; indeed, the biotech world tends to run on its own steam, and this stock seems to by capable of defying gravity;" says Mike Turner.

The editor of Trade of the Week explains, "The company, based in Foster City, California, has just about everything that I look for in a company and, by extension, its stock.

"True, the biotech sector cannot completely ignore the broader markets, but when a fundamentally and technically strong stock like this bubbles to the surface, I do not want to ignore it.

"Two of our long-standing buy recommendations are involved in selling products and services for the genetic research market: Affymetrix (AFFX) and Illumina (ILMN)," notes biotech and growth stock specialist Nate Pile.

The editor of Nate's Notes explains, "In a nutshell, both of these companies have developed technologies that allow researchers to do what is known as 'high-throughput genetic screening'.

"And, while the two companies are direct competitors in many of the markets in which they compete, we believe that both stocks should be bought at the current time.

Shares of biotech giant Amgen, Inc. (AMGN) are trading slightly higher in after hours trading this afternoon after the company delivered better than expected earnings for its second quarter.

Going into this afternoon's earnings report, analysts had been expecting to see Amgen report $1.30 per share, but the company was able to beat out analyst estimates by reporting an actual $1.38 for the quarter.

"We believe OncoGenex (OGXI) is undervalued relative to its peers," says biotech expert John McCamant.

The editor of The Medical Technology Stock Letter suggests, "One of the best ways to start evaluating development stage biotech stocks is to evaluate three fundamental considerations to begin the screening process. We ask, 'What is the market potential?' 'How long before the drug development candidate is likely to be approved?' and 'How much development risk remains?'

"Isis Pharmaceuticals (ISIS) stock is down over the last month on the continued controversy and misinformation surrounding the safety and potential market size for mipomersen;Wall Street has focused on some perceived safety issues from the release of Phase 3 data for mipomersen in heterozygous familial hypercholesterolemia (heFH) patients.," says John McCamant.

The editor of The Medical Technology Stock Letter explains, "The trial met its primary endpoint with a highly statistically significant 28% reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5% for placebo."

"Geron (GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes," says Tom Bishop.

In his BI Research advisory he explains, "The company is also a, if not the, world leader in the development of human embryonic stem cell-based therapeutics." Here's his in-deth analysis of the company.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Our top stock pick for 2010 is ImmunoGen (IMGN)," says biotech specialist John McCamant.

In his The Medical Technology Stock Letter, he explains, "The company's potent cancer-cell killing antibodies were developed for targeted delivery to tumor cells."

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Monsanto (MON) is my top investment idea for 2010," says Sy Harding, an advisor well-known for his seasonal timing strategies.

In his Street Smart Report, he observes, "Monsanto is the world's leading provider of biotech-advanced seeds and agricultural products for growers; seeds for corn, soybeans, cotton, fruit, and vegetables, which are produced by its genomics division."